Synexus Pushes Ahead with Central & Eastern Europe Expansion
Synexus has announced plans to open three new research centers in Bulgaria, Poland and Romania.
Synexus has announced plans to open three new research centers in Bulgaria, Poland and Romania, bringing the company’s total to nine centers in Central & Eastern Europe and a total network of 25 across Europe and Africa.
The population of Central and Eastern Europe exceeds that of either the US or the five largest Western European markets combined, and it also has excellent healthcare professionals, according to the U.K.-headquartered recruitment specialist.
“This will help us to provide much greater support to the global pharmaceutical industry,” noted CEO Christophe Berthoux. “Since we opened our first centre in Poland in 2006 we have had an ongoing programme of investment in the region.”
The new Polish facility is the company’s largest research center in the world. It occupies 1000 m2 at Beniowskiego Street in Gdansk. Magdalena Przekwas-Jaruchowska, M.D., the facility’s director, oversaw the opening ceremony, which included representatives from the local authority, the British Embassy, the medical university and patients’ associations.
Romania’s new 820 m2 center is based in Bucharest, which has a population of two million. The country has been part of Synexus’ development plans since early 2000, as the total population is over 20 million and the number of new clinical trials granted approval during the last five years is at least 200, according to the company.
In Sofia, Bulgaria, the total area of the new center is 650 m2, and it has eight medical rooms, two administration rooms, monitoring and meeting rooms and other areas. This facility aims to offer its patients access to new drugs in the fields of pulmonology, rheumatology, neurology, endocrinology, cardiology, gastroenterology and dermatology.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
